GlassScriptPhysician profile
Andrew Y Lin
NPI 1679635254
$37,507.37
in general payments reported to CMS, 2019-2025
48 companies · $2,840 in 2025
The $2,840 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,830 · 2020: $2,478 · 2021: $4,149 · 2022: $2,725 · 2023: $2,367 · 2024: $20K · 2025: $2,840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $18K · Food and Beverage: $7,325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $18,000.00 |
| Food and Beverage | $7,325.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $19,544.57 | 2021-2025 | Ensite, Gallant, Perclose Prostyle |
| Novo Nordisk INC | $2,159.55 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,575.14 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,399.95 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $1,352.44 | 2019-2025 | Otezla, Repatha, Evenity |
| Glaxosmithkline, LLC. | $1,256.84 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $1,139.27 | 2019-2024 | |
| Gilead Sciences, INC. | $1,108.52 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $1,031.37 | 2019-2023 | Xarelto |
| Amarin Pharma, INC. | $846.58 | 2019-2021 | |
| Esperion Therapeutics, INC. | $741.97 | 2020-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $613.65 | 2022-2024 | |
| Lilly USA, LLC | $473.30 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $367.23 | 2019-2022 | |
| Ibsa Pharma INC. | $349.61 | 2021-2025 | Tirosint, Licart, Tirosint |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.